In detail, the molecular subtyping of BC relies on the examination of crucial tumor markers through immunohistochemistry tests, such as estrogen receptor(ER), progesterone receptor (PR), HER2, Ki-67 and etc. (Table 1). This evidence concerns the gene ESR1 and neoplasm.